- Home
- CBNK vs ERAS Comparison
CBNK vs ERAS Comparison
Compare CBNK & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CBNK
- ERAS
- Stock Information
- Founded
- CBNK 1974
- ERAS 2018
- Country
- CBNK United States
- ERAS United States
- Employees
- CBNK N/A
- ERAS N/A
- Industry
- CBNK Major Banks
- ERAS Biotechnology: Pharmaceutical Preparations
- Sector
- CBNK Finance
- ERAS Health Care
- Exchange
- CBNK Nasdaq
- ERAS Nasdaq
- Market Cap
- CBNK 517.6M
- ERAS 484.4M
- IPO Year
- CBNK 2018
- ERAS 2021
- Fundamental
- Price
- CBNK $32.68
- ERAS $1.64
- Analyst Decision
- CBNK Hold
- ERAS Strong Buy
- Analyst Count
- CBNK 1
- ERAS 6
- Target Price
- CBNK $35.00
- ERAS $4.83
- AVG Volume (30 Days)
- CBNK 68.9K
- ERAS 796.3K
- Earning Date
- CBNK 07-28-2025
- ERAS 08-12-2025
- Dividend Yield
- CBNK 1.47%
- ERAS N/A
- EPS Growth
- CBNK 11.33
- ERAS N/A
- EPS
- CBNK 2.69
- ERAS N/A
- Revenue
- CBNK $205,155,000.00
- ERAS N/A
- Revenue This Year
- CBNK $47.27
- ERAS N/A
- Revenue Next Year
- CBNK $7.48
- ERAS N/A
- P/E Ratio
- CBNK $12.17
- ERAS N/A
- Revenue Growth
- CBNK 30.26
- ERAS N/A
- 52 Week Low
- CBNK $22.77
- ERAS $1.01
- 52 Week High
- CBNK $36.40
- ERAS $3.31
- Technical
- Relative Strength Index (RSI)
- CBNK 48.92
- ERAS 58.30
- Support Level
- CBNK $30.84
- ERAS $1.38
- Resistance Level
- CBNK $33.37
- ERAS $1.71
- Average True Range (ATR)
- CBNK 1.09
- ERAS 0.11
- MACD
- CBNK 0.10
- ERAS 0.01
- Stochastic Oscillator
- CBNK 55.20
- ERAS 78.95
About CBNK Capital Bancorp Inc.
Capital Bancorp Inc is a bank holding company. The company through its holdings operates as a commercial-focused community bank that serves businesses, not-for-profit associations, and entrepreneurs throughout the region. The bank operates through four divisions including Commercial Banking, Capital Bank Home Loans, OpenSky, and Windsor Advantage, and also operates in five business segments: commercial banking; mortgage banking; credit cards; government loan servicing; and corporate activities.
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.